Veracyte (NASDAQ:VCYT – Get Free Report) is scheduled to be releasing its earnings data after the market closes on Tuesday, August 6th. Analysts expect Veracyte to post earnings of ($0.03) per share for the quarter. Persons interested in registering for the company’s earnings conference call can do so using this link.
Veracyte (NASDAQ:VCYT – Get Free Report) last issued its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.17. Veracyte had a negative net margin of 18.16% and a negative return on equity of 1.42%. The company had revenue of $96.84 million during the quarter, compared to analysts’ expectations of $93.35 million. During the same quarter in the previous year, the company earned ($0.11) EPS. Veracyte’s revenue was up 17.5% on a year-over-year basis. On average, analysts expect Veracyte to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Veracyte Price Performance
Shares of NASDAQ:VCYT opened at $21.60 on Monday. Veracyte has a one year low of $18.61 and a one year high of $29.35. The company has a 50 day moving average of $22.18 and a 200-day moving average of $22.37. The stock has a market cap of $1.65 billion, a price-to-earnings ratio of -22.98 and a beta of 1.65.
Wall Street Analyst Weigh In
Get Our Latest Stock Report on Veracyte
Insider Activity at Veracyte
In other Veracyte news, Director Muna Bhanji sold 3,870 shares of Veracyte stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $20.32, for a total value of $78,638.40. Following the transaction, the director now owns 23,105 shares of the company’s stock, valued at $469,493.60. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other Veracyte news, Director Karin Eastham sold 7,500 shares of Veracyte stock in a transaction that occurred on Tuesday, July 16th. The shares were sold at an average price of $25.00, for a total value of $187,500.00. Following the transaction, the director now owns 33,228 shares of the company’s stock, valued at $830,700. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Muna Bhanji sold 3,870 shares of Veracyte stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $20.32, for a total transaction of $78,638.40. Following the completion of the transaction, the director now directly owns 23,105 shares in the company, valued at approximately $469,493.60. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 16,686 shares of company stock worth $382,807. 1.30% of the stock is currently owned by company insiders.
Veracyte Company Profile
Veracyte, Inc operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis.
Further Reading
- Five stocks we like better than Veracyte
- How to Choose Top Rated Stocks
- Market Crash? No Problem for DoorDash Stock’s Impressive Earnings
- What is the Nikkei 225 index?
- Snap’s Stock Plummets on Q2 Revenue Guidance Shortfall
- How to Find Undervalued Stocks
- Hims & Hers Stock Falls on DexCom Fears: Analysts Predict Rally
Receive News & Ratings for Veracyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veracyte and related companies with MarketBeat.com's FREE daily email newsletter.